How Five9’s New Epic Integration Could Shape Healthcare Growth Prospects for FIVN Investors

• Five9, Inc. recently announced the launch of Five9 Fusion for Epic, a fully native integration embedding advanced contact center functionality into the Epic electronic health record system, designed to streamline healthcare communications and enhance patient experiences for providers.
• This collaboration is a significant step for cloud-based healthcare technology, enabling agents to access patient data and communication tools in a unified environment while maintaining robust privacy controls.
• We'll examine how embedding contact center capabilities directly into Epic may reshape Five9's investment outlook, particularly for healthcare-focused growth.

The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Five9 Investment Narrative Recap

To be a Five9 shareholder, you need to believe in long-term demand for cloud-based intelligent contact center platforms, especially as healthcare digitizes. The Five9 Fusion for Epic product could support near-term growth in the healthcare vertical, but leadership transitions, particularly the recent CEO retirement, remain the biggest risk potentially affecting management execution more than this sector integration moves the needle in the short term.

Among recent announcements, Five9's launch of AI Agents significantly deepens its automation offering, reinforcing the view that advanced AI capabilities, now being integrated into healthcare settings like Epic, will remain a powerful sales catalyst.

But against these growth opportunities, the company’s upcoming leadership handover could create uncertainties that investors should be aware of if execution missteps arise…

Read the full narrative on Five9 (it's free!)

Five9's narrative projects $1.4 billion revenue and $98.5 million earnings by 2028. This requires 9.3% yearly revenue growth and an $89.7 million earnings increase from $8.8 million today.

Uncover how Five9's forecasts yield a $36.38 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have published 11 fair value estimates for Five9 in a wide band from US$36.38 to US$71.52. Despite this diversity, many agree that the pace of AI-driven product adoption across healthcare and enterprise could influence whether the recent Epic integration translates into broader outperformance.

Explore 11 other fair value estimates on Five9 - why the stock might be worth over 2x more than the current price!

Build Your Own Five9 Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Five9 research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Five9 research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Five9's overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com